SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : EntreMed (ENMD)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Sonny Blue who wrote (809)5/6/1998 7:07:00 PM
From: Secret_Agent_Man  Read Replies (2) of 2135
 
14:14 ET Oxigene (OXGN) 18 3/8 +4 (+28%): British doctors said they expect to
begin human trials of a new cancer drug that cuts off blood supply to tumors in six
months, ahead of U.S. biotechs which are working on a similar approach, according to
Reuters. Their wonder-drug, Combretastatin, was discovered by an Arizona State
University professor and has been licensed to Oxigene. Volume 1 mln shares. Stock also
trades warrants "OXGNW" (5 3/4 +2 3/8, +70%). EntreMed said it would be at least a
year before its drug is ready for human trials.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News